Adachi Masanori
J Pediatr Endocrinol Metab. 2013;26(11-12):1105-10. doi: 10.1515/jpem-2013-0071.
To assess the user-friendliness of the Norditropin FlexPro (Novo Nordisk A/S, Bagsvaerd, Denmark), a newly developed growth hormone (GH) injection pen.
This study consisted of a single-center, single-arm, open-label, questionnaire based survey of patients undergoing GH treatment for diverse indications who were scheduled to switch from the formerly used device Norditropin NordiFlex (Novo Nordisk A/S) to the FlexPro and evaluate each device's usability.
A total of 82 patients participated in the study. Compared to the NordiFlex, the FlexPro was regarded as easier to grip, easier to hold during injection, and more stable during injection. The degree of pain at insertion perceived by the patient and the patient's fear of injection were significantly decreased when using the FlexPro, and 81% of the respondents selected the FlexPro as the more preferable device.
The FlexPro was more user-friendly than the NordiFlex. Perception of pain at insertion and fear of injection were lessened by using the FlexPro.
评估新开发的生长激素（GH）注射笔诺和锐（丹麦 Bagsvaerd 的诺和诺德公司）的用户友好性。
本研究为单中心、单臂、开放标签、基于问卷的调查，对象为因各种适应症接受 GH 治疗且计划从以前使用的诺和笔更换为诺和锐的患者，并评估每种设备的易用性。
共有 82 名患者参与研究。与诺和笔相比，诺和锐被认为更容易握持、注射时更易于拿稳且注射过程中更稳定。使用诺和锐时患者在注射时感觉到的疼痛程度以及对注射的恐惧显著降低，81% 的受访者选择诺和锐作为更优的设备。
诺和锐比诺和笔对用户更友好。使用诺和锐可减轻对注射时疼痛的感知以及对注射的恐惧。
